Loading company
Inhibrx Biosciences, Inc.
INBX · Nasdaq · ·
$104.83+3.1%Sep 29 close
- 1M
- -15.1%
- 6M
- +75.1%
- 1Y
- +211.3%
INBX · Nasdaq · ·
$104.83+3.1%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$36.7M | -$28.7M | -27.91% |
| Profit per share | -$2.34 | -$1.85 | -26.49% |
| Free Cash Flow | -$29.9M | -$30M | +0.12% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Inhibrx Biosciences, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Inhibrx is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx’s current clinical pipeline of therapeutic candidates includes ozekibart and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what Inhibrx believes to be the most appropriate agonist function.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Inhibrx Biosciences, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.